Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 571, Issue 1, Pages 25-28Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2007.05.044
Keywords
vesicular monoamine transporter; VMAT; amphetamine; methylphenidate; synaptic vesicle; ADHD
Categories
Funding
- NIDA NIH HHS [K05 DA000378, R01 DA004222, DA11389, P01 DA013367-05, K05 DA000378-07, P01 DA013367, R01 DA004222-22, R01 DA011389, DA13367, R29 DA011389, R01 DA004222-21, P01 DA013367-06A2, R01 DA011389-10, R01 DA000869-32, DA04222, R01 DA000869-31, R01 DA011389-11A1, K05 DA000378-06, K02 DA019447-04, K02 DA019447-03, R01 DA000869, DA00869, K02 DA019447] Funding Source: Medline
Ask authors/readers for more resources
High-dose administration of psychostimulants traffics the vesicular monoamine transporter-2 (VMAT-2), as assessed by subcellular fractionation of rat striatal tissue. This study demonstrates that administration of low doses of amphetamine or methylphenidate differentially traffic VMAT-2 within nerve terminals, with effects similar to those observed after high-dose administration. Trafficking of vesicular glutamate, acetylcholine, or GABA transporters was not altered by high-or low-dose amphetamine or methylphenidate treatment. These data represent the first report that amphetamine redistributes VMAT-2 protein. In addition, these data demonstrate that the trafficking of VMAT-2 after amphetamine or methylphenidate is selective for monoaminergic neurons. (c) 2007 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available